Nebenwirkungen · Rydapt
Rydapt 25 mg soft capsules · Abschnitt 4.8 · PDF-Seite 9
HOS-135087 · Präparat HOS-097652
AML The safety evaluation of Rydapt (50 mg twice daily) in patients with newly diagnosed FLT3-mutated AML is based on a phase III, randomised, double-blind, placebo-controlled study with 717 patients. The overall median duration of exposure was 42 days (range 2 to 576 days) for patients in the Rydapt plus standard chemotherapy arm versus 34 days (range 1 to 465 days) for patients in the placebo plus standard chemotherapy arm. For the 205 patients (120 in Rydapt arm and 85 in placebo arm) who entered the maintenance phase, the median duration of exposure in maintenance was 11 months for both arms (16 to 520 days for patients in the Rydapt arm and 22 to 381 days in the placebo arm).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-14T02:00:00Z · SHA-256 8f1ec9efb6021159ac982022053e37b35f5bff1afb750b66862153d8db724917 · Passage a0721d63b65150fafefbe58df8d4ca157faf481f5a4889e1239d5c3fbed99a3e · Zeichen 31–720 im Abschnitt